Explore 3 Stock Ideas & Industry Insights Download Free Report

Adhera Therapeutics Inc

Company price
0.0001 USD 0.00(0%)
Last update at 2026-11-19T21:00:00Z
VOLUME
84001
Market Cap
0.00M

Momentum Score

…

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.00
Low
0.01
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Adhera Therapeutics Inc is a small, development-stage biopharmaceutical company listed on the OTC Pink market with limited public disclosure about its pipeline. Long-term growth may depend on advancing product candidates, securing regulatory approvals and entering partnerships, which could appeal to investors seeking high-upside biotech exposure.

Material investment risks include absence of commercial products, substantial financing and dilution risk, clinical development setbacks, and very low trading liquidity that can impede exits.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.13M
Revenue Per Share
0.01
Gross Profit TTM
-0.16M
Debt / Equity
-
ROE
-
Net Debt
8.55M
ROCE
5.77%
Diluted EPS TTM
-1.17

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -4.49M -2.11M -6.35M -3.77M -11.98M
Net income -4.49M 2.35M -7.78M -5.54M -12.64M
Selling general administrative 1.28M 1.62M 0.66M 1.20M 4.71M
Selling and marketing expenses - - 0.02M 0.84M 5.26M
Gross profit - - - 0.03M -0.16M
Reconciled depreciation - - - 0.02M 0.08M
Ebit - -1.62M -1.49M -2.07M -11.32M
Ebitda - -1.62M -0.81M -1.99M -11.23M
Depreciation and amortization - 0.00M 0.67M 0.08M 0.08M
Non operating income net other - - - 0.04M -
Operating income -1.28M -1.62M -0.67M -2.04M -11.32M
Other operating expenses - 1.62M 0.67M 2.04M 10.45M
Interest expense 3.19M 3.15M 1.43M 1.77M 0.66M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Net interest income -4.00M -3.15M -1.43M -1.77M -0.66M
Non recurring - - - - 1.12M
Income tax expense - -4.47M 1.43M 1.77M 0.66M
Total revenue 0.00M 0.00M 0.00M 0.13M 0.25M
Total operating expenses 1.28M 1.62M 0.67M 2.04M 10.04M
Cost of revenue - - - 0.10M 0.41M
Total other income expense net 0.80M -0.50M -5.68M -1.73M -0.66M
Net income from continuing ops -4.49M -2.11M -6.35M -3.77M -11.98M
Net income applicable to common shares - - -8.40M -5.31M -13.48M
Preferred stock and other adjustments - - - 1.54M 1.50M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 0.08M 0.20M 0.00M 0.42M 5.14M
Intangible assets - - - - 0.39M
Other current assets - - - 0.37M 0.16M
Total liab 22.27M 25.30M 14.77M 10.31M 2.21M
Total stockholder equity -22.19M -25.11M -14.77M -9.89M 2.93M
Other current liab 6.39M 13.17M 4.09M 2.56M 1.06M
Common stock - 0.10M 0.07M 0.07M 0.07M
Capital stock 0.02M 0.10M 0.07M 0.07M 0.06M
Retained earnings -55.75M -53.02M -44.61M -39.33M -25.85M
Good will - - - - 0.00M
Cash 0.03M 0.08M 0.00M 0.05M 3.92M
Total current liabilities 22.27M 25.30M 14.77M 10.31M 2.21M
Net debt 8.55M 6.59M 6.32M 5.28M -
Short term debt - - 6.32M 5.33M -
Short long term debt 8.59M 6.66M 6.32M 5.33M -
Property plant equipment - - - - 0.07M
Total current assets 0.08M 0.20M 0.00M 0.42M 4.68M
Net tangible assets - -25.11M -14.77M -9.89M 2.54M
Net receivables - - - 0.00M 0.05M
Inventory - - - 0.00M 0.24M
Accounts payable 2.40M 2.31M 8.46M 1.40M 0.29M
Common stock total equity - - 0.07M 0.07M -
Retained earnings total equity - - -44.61M -39.33M -
Non currrent assets other - - - 0.00M 0.46M
Non current assets total 0.00M 0.00M 0.00M 0.00M 0.46M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments - - - - 0.00M
Change to liabilities - - 0.09M 1.03M 0.94M
Net borrowings - - 0.84M 0.54M -0.71M
Total cash from financing activities 0.61M 1.37M 0.74M 0.54M 4.87M
Change to operating activities - - -0.09M 0.54M -0.43M
Net income -4.49M -2.11M -6.35M -3.77M -11.98M
Change in cash -0.10M -0.04M 0.07M -0.05M -3.87M
Begin period cash flow 0.13M 0.08M 0.00M 0.05M 3.92M
End period cash flow 0.03M 0.03M 0.07M 0.00M 0.05M
Total cash from operating activities -0.71M -1.42M -0.67M -0.59M -8.74M
Issuance of capital stock - - - - 0.00M
Depreciation - 1.81M 0.40M 0.40M 0.08M
Dividends paid - 0.62M 2.05M 1.54M 1.50M
Change to inventory - - -0.12M -0.01M -0.24M
Change to account receivables - - 0.12M 0.04M 0.02M
Sale purchase of stock 0.00M -0.00M -0.74M -0.54M -0.10M
Other cashflows from financing activities - -0.35M 2.79M 2.08M 6.38M
Change to netincome - - 5.28M 0.94M 2.30M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change receivables - - - - 0.02M
Cash flows other operating - - - 0.37M -0.22M
Cash and cash equivalents changes - - - -0.05M -3.87M
Change in working capital 0.63M 0.20M 0.01M 1.40M 0.48M
Stock based compensation - - 0.00M 0.01M 0.77M
Other non cash items 3.94M 0.50M 5.28M 1.77M 0.68M
Free cash flow -0.71M -1.42M -0.67M -0.59M -8.74M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ATRX
Adhera Therapeutics Inc
-
-%
0.00 - - 8.23 - 54.79 11.45
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Adhera Therapeutics Inc

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.

8000 Innovation Parkway, Baton Rouge, LA, United States, 70820

919 518 3748

2

Name Title Year Born
Dr. Zahed Subhan B.S., BS, L.L.B., LLB (Law), M.B.A., M.S., MBA, MS CEO, Chief Scientific Officer & Chairman 1958
Mr. Andrew Albert Kucharchuk M.B.A. Vice Chairman, COO, Acting CFO & Chief Bus. Officer 1981
Mr. Andrew Albert Kucharchuk M.B.A. Vice Chairman, COO, Acting CFO & Chief Business Officer 1981
Mr. Andrew Albert Kucharchuk M.B.A. Vice Chairman, COO & Chief Business Officer 1981

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…